Enhanced recovery after surgery (ERAS) in gynecology oncology.


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
May 2021
Historique:
received: 13 09 2020
revised: 11 10 2020
accepted: 26 10 2020
pubmed: 4 11 2020
medline: 7 10 2021
entrez: 3 11 2020
Statut: ppublish

Résumé

The Enhanced Recovery After Surgery (ERAS) is a pathway designed to achieve early recovery for patients undergoing major surgery. The ERAS pathway included three important components preoperative, intraoperative, postoperative program. Pre-habilitation and re-habilitation are of paramount importance to improve patients' care. The ERAS is based on evidence-based medicine. Accumulating evidence highlighted that adopting ERAS resulted in lower complication rate, and shorter length of hospital stay in comparison to standard protocols of care. The adoption of the ERAS resulted in a significant improvement of patients' outcomes and a reduction of the overall cost of care. In the present review, we summarized current evidence on ERAS, focusing on the steps useful for its adoption into clinical practice.

Identifiants

pubmed: 33139130
pii: S0748-7983(20)30867-2
doi: 10.1016/j.ejso.2020.10.030
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

952-959

Informations de copyright

Copyright © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The Authors declare no conflicts of interest. No funding sources supported this investigation.

Auteurs

Giorgio Bogani (G)

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy. Electronic address: giorgiobogani@yahoo.it.

Giuseppe Sarpietro (G)

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

Gabriella Ferrandina (G)

UOC Ginecologia Oncologica, Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italy; Universita' Cattolica, Roma, Italy.

Valerio Gallotta (V)

UOC Ginecologia Oncologica, Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italy.

Violante DI Donato (V)

Department of Maternal and Child Health and Urological Sciences, "Sapienza" University of Rome, Rome, Italy.

Antonino Ditto (A)

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

Ciro Pinelli (C)

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; University of Insubria, Ospedale di Circolo Fondazione Macchi, Varese, Italy.

Jvan Casarin (J)

University of Insubria, Ospedale di Circolo Fondazione Macchi, Varese, Italy.

Fabio Ghezzi (F)

University of Insubria, Ospedale di Circolo Fondazione Macchi, Varese, Italy.

Giovanni Scambia (G)

UOC Ginecologia Oncologica, Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italy; Universita' Cattolica, Roma, Italy.

Francesco Raspagliesi (F)

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH